LeMaitre Vascular, Inc. (LMAT) vs Nuvalent Inc (NUVL)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| LMAT | NUVL | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Biotechnology |
| Size band | SMALL | MID |
| Listing | Nasdaq GM | Nasdaq GM |
| Country | United States | United States |
| Theme | medical-devices | oncology |
| Price and returns | ||
| Last close | $84.31 | $123.96 |
| Return · 1 week | +2.43% | 0.00% |
| Return · 1 month | +2.39% | 0.00% |
| Return · 3 months | −17.59% | 0.00% |
| Return · year to date | +5.67% | +22.93% |
| Return · 1 year | −5.78% | +26.87% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −28.56% | −0.02% |
| 52-week high | $118.01 | $123.99 |
| 52-week low | $78.22 | $87.30 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $1.93B | $9.79B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $23.27M | $149.69M |
| Employees | 646 | 234 |
| Valuation | ||
| Price to earnings · trailing | 27.92× | n/a (negative earnings) |
| Price to earnings · forward | 25.38× | n/a (negative forward earnings) |
| Price to sales | 7.03× | — |
| Price to book | 4.39× | 8.33× |
| Enterprise value to EBITDA | 19.61× | — |
| Enterprise value to revenue | 6.20× | — |
| PEG ratio | 2.09 | — |
| Earnings per share · trailing | 2.89 | -6.06 |
| Profitability | ||
| Gross margin | 72.90% | — |
| Operating margin | 28.98% | 0.00% |
| Profit margin | 25.02% | — |
| Return on equity | 16.77% | −41.19% |
| Return on assets | 7.44% | −22.51% |
| Growth | ||
| Revenue growth | +9.60% | — |
| Earnings growth | +22.60% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 45.26 | — |
| Current ratio | 16.31 | 16.14 |
| Dividend yield | 1.26% | — |
| Payout ratio | 31.58% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 57.15 | — |
| ADX · 14 | 15.30 | — |
| 50-day average | $81.15 | — |
| 200-day average | $94.49 | — |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.54% | — |
The full LMAT analysis
Everything this table leaves out for LeMaitre Vascular, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the LMAT argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full LMAT analysisThe full NUVL analysis
Everything this table leaves out for Nuvalent Inc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NUVL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NUVL analysis